The nation of Zimbabwe has turned down a significant US healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to the United States' insistence on confidential biological samples.
This move became public following a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman has since explained that the US was demanding access to health data for research and commercial purposes while was not willing to share the benefits from future vaccines.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued negotiations to secure a deal agreeable to both sides so the country's vital HIV treatment initiative can proceed.
Broader Background
Zimbabwe's decision follows a comparable situation in Kenya, where a court suspended a similar health funding agreement following legal challenges were raised about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral deals to boost openness and responsibility.
As per statements, 16 African countries have to date agreed to these new health pacts, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to share its biological resources and data over an extended period, without any corresponding assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our nation would supply the raw materials for medical research with no certainty that the final treatments would be accessible to our people if a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting structures already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This system is intended to guarantee that when a country provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We are open to continued discussions with our American counterparts on how subsequent collaboration could be structured in a way that honours the independence and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it understood the official position, but recommended that talks must proceed since a large portion of the nation's Aids initiatives were funded by foreign aid.
"In cases where technical issues arise, including those involving information security or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," the group added.
The halted deal emphasises the continuing challenges between accepting crucial international aid and safeguarding national sovereignty in an ever more data-driven world.